8-K: Inhibikase Advances PAH Drug to Pivotal Phase 3 Study

Inhibikase Therapeutics, Inc. announced it will advance its IKT-001 drug directly to a global pivotal Phase 3 clinical study for Pulmonary Arterial Hypertension (PAH) in Q1 2026, following FDA feedback.

Summary

• IKT-001 is advancing directly to a global pivotal Phase 3 clinical study, named IMPROVE-PAH, for Pulmonary Arterial Hypertension (PAH), with initiation expected in the first quarter of 2026.
• The company previously planned a Phase 2b study but, following a Type C meeting and Written Response from the U.S. Food & Drug Administration (FDA), will now proceed with a single pivotal Phase 3 study.
• The IMPROVE-PAH study will be a two-part adaptive Phase 3 design: Part A will enroll 140 patients with a primary endpoint of Pulmonary Vascular Resistance (PVR) at Week 24, and Part B will enroll 346 patients with a primary endpoint of 6-Minute Walk Distance (6MWD) at Week 24.
• Key advantages of the adaptive design include a 12-week dose-titration phase, uninterrupted enrollment between parts, and the ability to re-estimate sample size for Part B based on Part A findings.
• The study is expected to be conducted in up to approximately 180 sites worldwide.
• The company terminated the sales agreement prospectus (ATM Prospectus) related to its Open Market Sale AgreementSM with Jefferies LLC, effective November 20, 2025; no sales were made under this prospectus, and no future sales will occur without a new prospectus.
• PAH is a rare, progressive, and life-threatening disease with a significant unmet need, characterized by approximately 30% 5-year mortality and a $7.6 billion market.
• IKT-001 is an investigational novel pro-drug of imatinib, engineered for better gastrointestinal (GI) tolerability to realize imatinib's potential best-in-class efficacy in PAH.
• Previous studies with imatinib demonstrated significant improvements in PVR and 6MWD (up to 45 meters) but faced high discontinuation rates due to GI adverse events.

Sentiment

Score: 8

Explanation: The direct advancement to a pivotal Phase 3 study for IKT-001 in PAH, supported by FDA feedback, significantly de-risks the development pathway and accelerates the potential time to market. The drug's mechanism (imatinib pro-drug) has demonstrated strong efficacy in previous studies, and the improved tolerability profile of IKT-001 addresses a critical historical hurdle. Targeting a $7.6 billion market with high unmet need, this development positions Inhibikase for substantial future growth. The termination of the ATM prospectus is a minor negative in the context of overall positive clinical development news.

Positives

• Direct advancement to a pivotal Phase 3 study for IKT-001 in PAH, bypassing a Phase 2b study, potentially accelerating the development timeline.
• FDA feedback supports the single pivotal Phase 3 study design, providing regulatory clarity and confidence.
• The adaptive two-part Phase 3 study design offers strategic flexibility, including a 12-week dose-titration phase, uninterrupted enrollment, and the ability to re-estimate sample size.
• IKT-001 is a pro-drug of imatinib, engineered for improved GI tolerability, which addresses a critical issue that led to high discontinuation rates and non-approval of imatinib in previous Phase 3 trials.
• Imatinib, the active compound, has demonstrated significant efficacy in previous Phase 3 (IMPRES) and Phase 2 studies, including a 32-meter improvement in 6MWD and a 32% reduction in PVR, with a 45-meter improvement at optimal dosing.
• Pulmonary Arterial Hypertension (PAH) represents a large market opportunity, estimated at $7.6 billion, with a high unmet medical need for disease-modifying treatments.
• The company holds intellectual property (NCE) runway for IKT-001 through 2044, providing long-term market exclusivity.
• The company has an experienced leadership team with deep expertise in PAH and cardiovascular development.

Negatives

• The termination of the ATM Prospectus means the company cannot currently raise capital through this specific mechanism without filing a new prospectus, potentially limiting immediate financing flexibility.
• No sales were made pursuant to the ATM Prospectus prior to its termination, indicating no capital was raised through this facility.
• The active compound, imatinib, previously faced high discontinuation rates in Phase 3 trials (IMPRES) due to adverse events, primarily GI-related, despite demonstrating efficacy.

Risks

• The ability to commence and successfully execute the Phase 3 trial to evaluate IKT-001 as a treatment for PAH.
• Actual results may differ materially from forward-looking statements due to inherent risks and uncertainties in clinical trials, regulatory approvals, and product candidate development.
• Factors included in the company's periodic reports on Form 10-K and Form 10-Q could cause actual results to differ materially.
• The company undertakes no obligation to publicly update or revise any forward-looking statement, except as required by applicable securities laws.

Future Outlook

The company expects to initiate the IMPROVE-PAH Phase 3 study in Q1 2026, with Part A's PVR readout anticipated by mid-2028 and Part B's 6MWD topline readout by mid-2029. The company also plans to file for Orphan Drug Designation by mid-2026.

Industry Context

Pulmonary Arterial Hypertension (PAH) is a rare, progressive, and life-threatening disease affecting approximately 50,000 people in the U.S. and 26,000 in the EU5, with a high 5-year mortality rate of ~30% despite aggressive treatment. The global PAH market is estimated at $7.6 billion, primarily driven by vasodilator therapies that do not address the underlying cellular proliferation. Novel anti-proliferative agents like IKT-001, which target the underlying etiology, are expected to revolutionize treatment by offering disease-modifying properties.

Comparison to Industry Standards

• Imatinib (the active drug in IKT-001) demonstrated comparable efficacy to Sotatercept (P3 STELLAR) in improving 6MWD, with a median treatment difference of 32m for Imatinib (IMPRES) versus 33.4m for Sotatercept, although these were not head-to-head trials and had different designs.
• The Phase 3 IMPRES study showed a placebo-adjusted 32-meter improvement in 6MWD and a 32% reduction in PVR at week 24 for imatinib.
• Patients able to sustain a 400mg dose of imatinib in IMPRES showed a 45-meter placebo-adjusted 6MWD improvement at Week 24.
• A contemporary open-label study of imatinib in PAH (Rothman et al., AJRCCM 2025) reported a 24% reduction in Total Pulmonary Resistance (TPR) and early, sustained hemodynamic effects, suggesting disease modification.

Stakeholder Impact

• Shareholders: Potential for significant value creation if the Phase 3 study is successful, but also exposure to inherent clinical trial risks. The termination of the ATM prospectus may impact short-term financing flexibility.
• Patients (PAH): Offers hope for a new, potentially disease-modifying oral treatment with an improved tolerability profile for a severe, life-threatening condition with high unmet medical need.
• Investment Professionals/Analysts: Provides a clear development pathway and detailed timelines for IKT-001, enabling more informed valuation models and risk assessments.

Next Steps

• Initiate the IMPROVE-PAH Phase 3 study in Q1 2026.
• Enroll the first patient in Part A of IMPROVE-PAH in Q1 2026.
• File for Orphan Drug Designation by mid-2026.
• Conduct an interim safety readout for Part A of IMPROVE-PAH (n=50) in 1H 2027.
• Complete last patient enrollment in Part A and enroll the first patient in Part B (6MWD) of IMPROVE-PAH in 2H 2027.
• Conduct an unblinded PVR reduction readout for Part A of IMPROVE-PAH (n=120) by mid-2028.
• Complete enrollment for Part B of IMPROVE-PAH (n=346) by end 2028.
• Announce topline readout (6MWD) from Part B of IMPROVE-PAH (n=300) by mid-2029.

Key Dates

Recommendation

The direct progression to a pivotal Phase 3 study for IKT-001 in PAH, supported by FDA feedback, significantly de-risks the development pathway and accelerates the potential time to market. The drug's mechanism (imatinib pro-drug) has demonstrated strong efficacy in previous studies, and the improved tolerability profile of IKT-001 addresses a critical historical hurdle. Targeting a $7.6 billion market with high unmet need, this development positions Inhibikase for substantial future growth, making it an attractive long-term investment despite inherent clinical trial risks.

Keywords

Pulmonary Arterial Hypertension, PAH, IKT-001, Phase 3 Clinical Trial, FDA, Tyrosine Kinase Inhibitor, TKI, Imatinib, Orphan Disease, Drug Development, Biotechnology, Pharmaceutical